keyword
MENU ▼
Read by QxMD icon Read
search

basdai

keyword
https://www.readbyqxmd.com/read/28516874/long-term-effects-of-interleukin-17a-inhibition-with-secukinumab-in-active-ankylosing-spondylitis-3-year-efficacy-and-safety-results-from-an-extension-of-the-phase-3-measure-1-trial
#1
Xenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, Jürgen Braun, James C Wei, Eumorphia Maria Delicha, Zsolt Talloczy, Brian Porter
OBJECTIVES: Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3 MEASURE 1 trial. Here, we report efficacy and safety after 3 years of treatment. METHODS: AS subjects completing 2 years of treatment every 4 weeks with subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) entered a separate 3-year extension study (NCT01863732)...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28514405/-stable-high-interleukin-17a-concentration-in-patients-with-ankylosing-spondylitis-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-during-a-year
#2
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan
AIM: To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. SUBJECTS AND METHODS: Examinations were made in 30 patients (22 (73.3%) men) aged 38.35±9.19 years with AS (modified New-York criteria, BASDAI ≥4.0; AS duration, 11.4±9.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1±7.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg/kg body weight during a year according to the recommended regimen...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28507445/evaluation-of-fatigue-and-its-correlation-with-quality-of-life-index-anxiety-symptoms-depression-and-activity-of-disease-in-patients-with-psoriatic-arthritis
#3
Claudio Carneiro, Mario Chaves, Gustavo Verardino, Ana Paula Frade, Pedro Guimaraes Coscarelli, Washington Alves Bianchi, Marcia Ramos-E-Silva, Sueli Carneiro
BACKGROUND: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue. OBJECTIVES: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity. PATIENTS AND METHODS: This cross-sectional study was performed on outpatients with psoriatic arthritis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28498975/sustained-efficacy-safety-and-patient-reported-outcomes-of-certolizumab-pegol-in-axial-spondyloarthritis-4-year-outcomes-from-rapid-axspa
#4
Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar
Objective.: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods.: RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease...
May 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/28496443/higher-levels-of-secretory-iga-are-associated-with-low-disease-activity-index-in-patients-with-reactive-arthritis-and-undifferentiated-spondyloarthritis
#5
Fabián Salas-Cuestas, Wilson Bautista-Molano, Juan M Bello-Gualtero, Ivonne Arias, Diana Marcela Castillo, Lorena Chila-Moreno, Rafael Valle-Oñate, Daniel Herrera, Consuelo Romero-Sánchez
INTRODUCTION: Both reactive arthritis (ReA) and undifferentiated spondyloarthritis (uSpA) belong to the group of autoinflammatory diseases called spondyloarthritis (SpA). Hypotheses have been proposed about a relationship between the intestinal mucosa and inflammation of joint tissues. The role of immunoglobulin IgA or secretory immunoglobulin A (SIgA) in the inflammatory and/or clinical activity of patients with SpA remains poorly understood. OBJECTIVE: To evaluate the status of total IgA and SIgA, and the association among the levels of SIgA, IgA, IgA anti-Chlamydia trachomatis, and anti-Shigella spp...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28488046/features-of-the-achilles-tendon-paratenon-and-enthesis-in-inflammatory-rheumatic-diseases-a%C3%A2-clinical-and-ultrasonographic-study
#6
H Harman, E Süleyman
AIM: We analyzed the ultrasonographic (US) features of the Achilles tendon (AT), paratenon (AP), and enthesis in patients with axial spondyloarthropathies (SpA) and rheumatoid arthritis (RA), and compared these to healthy subjects. Relationships between these findings and clinical and functional parameters were identified. METHODS: The study included 40 axial SpA and 27 RA patients, as well as 30 healthy subjects. Clinical evaluation relied on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), AS Quality of Life Questionnaire (ASQoL), Disease Activity Score 28 (DAS28), and Health Assessment Questionnaire (HAQ), as well as on a visual analog scale (VAS) for entheseal pain and the Madrid Sonographic Enthesistis Index (MASEI)...
May 9, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28482137/effects-of-long-term-etanercept-treatment-on-clinical-outcomes-and-objective-signs-of-inflammation-in-early-non-radiographic-axial-spondyloarthritis-104-week-results-from-the-embark-study
#7
Maxime Dougados, Désirée van der Heijde, Joachim Sieper, Jürgen Braun, Gustavo Citera, Jan Lenaerts, Filip van den Bosch, James Cheng-Chung Wei, Ron Pedersen, Randi Bonin, Heather Jones, Lisa Marshall, Isabelle Logeart, Bonnie Vlahos, Jack F Bukowski, Walter P Maksymowych
OBJECTIVE: To evaluate the long-term clinical and imaging efficacy of etanercept in patients with early, active non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: Adult patients who satisfied Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, with symptom duration >3 months to <5 years, and who were unresponsive to ≥2 NSAIDs, received double-blind etanercept 50 mg/week or placebo for 12 weeks, followed by open-label etanercept 50 mg/week to week 104...
May 8, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28434410/dosage-and-duration-of-etanercept-therapy-for-ankylosing-spondylitis-a-meta-analysis
#8
Heeyoung Lee, Younjoo Jung, Seungyeon Song, Jihyung Lee, Hyunjun Shim, Wonku Kang, Eunyoung Kim
OBJECTIVES: We conducted a meta-analysis of recently published randomized controlled trials (RCTs) to identify the most effective and safe etanercept dosing regimen and duration of therapy for the treatment of patients with ankylosing spondylitis (AS). METHODS: We systematically reviewed PubMed, Embase, Cochrane Library, and Web of Science databases for RCTs. The proportion of patients attaining 20 percent improvement (according to the Spondyloarthritis International Society response criteria [ASAS 20]) was evaluated as a primary outcome...
April 24, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28421263/bone-mineral-density-and-fracture-risk-in-ankylosing-spondylitis-a-meta-analysis
#9
Cara Pray, Neelufor Irene Feroz, Nisha Nigil Haroon
We conducted a meta-analysis of studies to examine the risk of vertebral and non-vertebral fractures in patients with ankylosing spondylitis (AS). Additionally, we evaluated the risk factors of vertebral fractures in AS. Two authors independently searched Embase and Medline for studies that had assessed the risk of fractures in patients with AS. Twenty-two studies were eligible for the meta-analysis. Patients with AS had high frequency of vertebral fractures [OR (95% CI): 1.96 (1.52-2.51)]. Major risk factors for vertebral fractures in patients with AS include low BMD at the femoral neck and total hip, male gender, longer disease duration, higher BASDAI, higher BASRI, and possibly inflammatory bowel disease...
April 18, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28403136/influence-of-cyp2c9-and-cox-2-genetic-polymorphisms-on-clinical-efficacy-of-non-steroidal-anti-inflammatory-drugs-in-treatment-of-ankylosing-spondylitis
#10
Yu Wang, Xiao-Dong Yi, Hai-Lin Lu
BACKGROUND The aim of this study was to evaluate the relationships of CYP2C9 and COX-2 genetic polymorphisms with therapeutic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in treatment of ankylosing spondylitis (AS). MATERIAL AND METHODS We enrolled 130 AS inpatients and outpatients in the Arthritis and Rheumatism Department of Peking University First Hospital and 106 healthy people getting routine check-ups between September 2013 and July 2014. CYP2C9 and COX-2 genetic polymorphisms were detected by PCR-RFLP...
April 12, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28379663/erectile-dysfunction-in-ankylosing-spondylitis-patients
#11
Thiago Santana, Thelma Skare, Vitor Steil Delboni, Juliana Simione, Ana Paula B Campos, Renato Nisihara
BACKGROUND: Rheumatic diseases such as ankylosing spondylitis (AS) may be associated with sexual dysfunction. AIM: To study erectile function of a group of Brazilian AS patients comparing them with controls. MATERIALS AND METHODS: This was a cross sectional study approved by the local Committee of Ethics in Research. The questionnaire IIEF (International Index of Erectile Function) was applied to 40 AS patients and 40 healthy controls. AS patients had determination of disease activity (through BASDAI or Bath Ankylosing Spondylitis Disease activity index), ASDAS (Ankylosing Spondylitis Disease Activity Score, MASES or Maastricht Ankylosing Spondylitis Score and SPARCC or Spondyloarthritis Research Consortium of Canada), function (through BASFI or Bath Ankylosing Spondylitis Functional Index and HAQ or Health Assessment Questionnaire) and BASMI (Bath Ankylosing Spondylitis Metrological Index)...
April 6, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28378098/association-of-obesity-with-patient-reported-outcomes-in-patients-with-axial-spondyloarthritis-a-cross-sectional-study-in-an-urban-asian-population
#12
Yi Xuan Lee, Yu Heng Kwan, Wan Yu Png, Ka Keat Lim, Chuen Seng Tan, Nai Lee Lui, Eng Hui Chew, Julian Thumboo, Truls Østbye, Warren Fong
To determine if obesity is associated with poorer patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA), we conducted a cross-sectional study using data of the PRESPOND registry from a tertiary referral center in Singapore between 2011 and 2015. Demographics, clinical, and PRO variables were collected. Patients were divided into three categories: normal (BMI < 23 kg/m(2)), overweight (23 kg/m(2) ≤ BMI < 27.5 kg/m(2)) and obese (BMI ≥ 27.5 kg/m(2)), using Asian BMI classification...
April 4, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28362980/role-of-th1-th2-cytokines-in-the-diagnosis-and-prognostic-evaluation-of-ankylosing-spondylitis
#13
J T Wen, D H Zhang, P F Fang, M H Li, R J Wang, S H Li
Ankylosing spondylitis (AS), a progressive disease of the spine, manifests as peripheral arthritis with tendon and ligament inflammation that restricts activity. AS is a rheumatoid autoimmune disease although the rheumatoid factor is absent in patients with AS. It is characterized by inflammatory changes such as elevated levels of serum inflammatory factors. The roles of Th1 and Th2 cytokines in autoimmune diseases are well known. However, the roles of these cytokines in the diagnosis and prognosis of AS is poorly understood...
March 16, 2017: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28293446/real-life-experience-of-using-conventional-disease-modifying-anti-rheumatic-drugs-dmards-in-psoriatic-arthritis-psa-retrospective-analysis-of-the-efficacy-of-methotrexate-sulfasalazine-and-leflunomide-in-psa-in-comparison-to-spondyloarthritides-other-than-psa
#14
Euthalia Roussou, Aicha Bouraoui
OBJECTIVE: With the aim of assessing the response to treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) used in patients with psoriatic arthritis (PsA), data on methotrexate, sulfasalazine (SSZ), and leflunomide were analyzed from baseline and subsequent follow-up (FU) questionnaires completed by patients with either PsA or other spondyloarthritides (SpAs). MATERIAL AND METHODS: A single-center real-life retrospective analysis was performed by obtaining clinical data via questionnaires administered before and after treatment...
March 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28279855/anti-therapeutic-antibodies-and-their-clinical-impact-in-patients-treated-with-the-tnf-antagonist-adalimumab
#15
Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini, Meenu Wadhwa
Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS)...
March 6, 2017: Cytokine
https://www.readbyqxmd.com/read/28248857/correlations-of-cyp2c9-3-cyp2d6-10-cyp3a5-3-gene-polymorphisms-with-efficacy-of-etanercept-treatment-for-patients-with-ankylosing-spondylitis-a-case-control-study
#16
Yuan-Yuan Chen
BACKGROUND: The tumor necrosis factor alpha (TNF-α) inhibitor etanercept has been proven to be effective in the treatment of ankylosing spondylitis (AS), while genetic polymorphism may affect drug metabolism or drug receptor, resulting in interindividual variability in drug disposition and efficacy. The purpose of this study is to investigate the correlations between CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms and the efficacy of etanercept treatment for patients with AS. METHODS: From March 2012 to June 2015, 312 AS patients (174 males and 138 females, mean age: 35...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28248799/the-effectiveness-of-structured-group-education-on-ankylosing-spondylitis-patients
#17
Meliha Kasapoglu Aksoy, Murat Birtane, Nurettin Taştekin, Galip Ekuklu
BACKGROUND: Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease that affects the axial skeleton which can lead to structural and functional impairments. It has a negative impact on the person's daily life activities. Early diagnosis, exercise and patient education are factors playing a major role on prognosis. OBJECTIVE: The purpose of the study was to compare the structured theoretical and exercise educational program with routine clinic educational efforts on the parameters of the disorder over a 3 month follow up...
April 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28240589/fatigue-contributes-to-work-productivity-impairment-in-patients-with-axial-spondyloarthritis-a-cross-sectional-uk-study
#18
Shima Espahbodi, Paul Bassett, Charlotte Cavill, Mandy Freeth, John Hole, Raj Sengupta
OBJECTIVES: To determine factors associated with absenteeism, presenteeism, work productivity loss (WPL), and daily activity impairment in UK patients with AxSpA using standardised measures. METHODS: 490 patients with AxSpA completed (1) Work Productivity and Impairment questionnaire (WPAI), providing measures for absenteeism, presenteeism, WPL and daily activity impairment, and (2) BASDAI, BASFI, BASMI, Jenkins Sleep scale, Patient Global Assessment disease activity (PGA), back pain night and anytime, EQ-5D for mobility, self-care, daily activities, pain/discomfort, anxiety/depression, EQ-VAS Health State Today, FACIT fatigue, for health-related disease factors...
February 24, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28240587/evaluation-of-whether-extremely-high-enthesitis-or-bath-ankylosing-spondylitis-disease-activity-index-basdai-scores-suggest-fibromyalgia-and-confound-the-anti-tnf-response-in-early-non-radiographic-axial-spondyloarthritis
#19
Maxime Dougados, Isabelle Logeart, Annette Szumski, Javier Coindreau, Heather Jones
OBJECTIVES: Differentiating between pain from spondyloarthritis (SpA) and pain from fibromyalgia is challenging. We evaluated patients with non-radiographic axial SpA (nr-axSpA) to determine the percentage of patients with extremely high enthesitis and/or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, the relationship between extreme scores and depression, and the effect of extreme scores on treatment outcomes with etanercept. METHODS: Patients with nr-axSpA received double-blind etanercept 50 mg or placebo weekly and were divided into those who did vs did not have extreme scores at baseline...
February 23, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28179619/rituximab-can-induce-remission-in-a-patient-with-ankylosing-spondylitis-who-failed-anti-tnf-%C3%AE-agent
#20
Fahmi AlDhaheri, Talal Almteri, Naji Dwid, Ahd Majdali, Nahed Janoudi, Hani Almoallim
BACKGROUND Ankylosing spondylitis (AS) is a chronic inflammatory disease that predominantly affects the axial skeleton. The ability of anti-TNF-α agents to reduce disease activity in patients with axial spondyloarthritis (axSpA), including AS, has been demonstrated in multiple randomized trials and several meta-analyses. Reports on the efficacy of rituximab in treatment of AS have described good results. We report on a patient with AS who failed anti-TNF-α therapy but showed good clinical improvement with rituximab therapy...
February 9, 2017: American Journal of Case Reports
keyword
keyword
116433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"